Daesung Microbiological Labs. Co. Ltd (036480) - Total Assets
Based on the latest financial reports, Daesung Microbiological Labs. Co. Ltd (036480) holds total assets worth ₩57.98 Billion KRW (≈ $39.29 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Daesung Microbiological Labs. Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
Daesung Microbiological Labs. Co. Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Daesung Microbiological Labs. Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore 036480 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Daesung Microbiological Labs. Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Daesung Microbiological Labs. Co. Ltd's total assets of ₩57.98 Billion consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.9% |
| Accounts Receivable | ₩5.02 Billion | 8.7% |
| Inventory | ₩10.55 Billion | 18.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩428.67 Million | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Daesung Microbiological Labs. Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 036480 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daesung Microbiological Labs. Co. Ltd's current assets represent 43.5% of total assets in 2025, an increase from 41.6% in 2012.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, up from 5.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 18.2% of total assets.
Daesung Microbiological Labs. Co. Ltd Competitors by Total Assets
Key competitors of Daesung Microbiological Labs. Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Daesung Microbiological Labs. Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 5.22 | 6.73 |
| Quick Ratio | 1.72 | 2.90 | 4.06 |
| Cash Ratio | 0.00 | 0.80 | 0.00 |
| Working Capital | ₩16.70 Billion | ₩19.11 Billion | ₩19.31 Billion |
Daesung Microbiological Labs. Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Daesung Microbiological Labs. Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -0.7% |
| Total Assets | ₩57.98 Billion |
| Market Capitalization | $16.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daesung Microbiological Labs. Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Daesung Microbiological Labs. Co. Ltd's assets decreased by 0.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Daesung Microbiological Labs. Co. Ltd (2012–2025)
The table below shows the annual total assets of Daesung Microbiological Labs. Co. Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩57.98 Billion ≈ $39.29 Million |
-0.69% |
| 2024-12-31 | ₩58.38 Billion ≈ $39.56 Million |
-9.19% |
| 2023-12-31 | ₩64.29 Billion ≈ $43.57 Million |
-1.26% |
| 2022-12-31 | ₩65.11 Billion ≈ $44.12 Million |
+3.98% |
| 2021-12-31 | ₩62.62 Billion ≈ $42.44 Million |
+0.57% |
| 2020-12-31 | ₩62.26 Billion ≈ $42.19 Million |
+22.64% |
| 2019-12-31 | ₩50.77 Billion ≈ $34.40 Million |
+33.25% |
| 2018-12-31 | ₩38.10 Billion ≈ $25.82 Million |
+9.53% |
| 2017-12-31 | ₩34.78 Billion ≈ $23.57 Million |
-2.32% |
| 2016-12-31 | ₩35.61 Billion ≈ $24.13 Million |
+9.84% |
| 2015-12-31 | ₩32.42 Billion ≈ $21.97 Million |
+16.65% |
| 2014-12-31 | ₩27.79 Billion ≈ $18.83 Million |
-3.99% |
| 2013-12-31 | ₩28.95 Billion ≈ $19.62 Million |
+13.55% |
| 2012-12-31 | ₩25.49 Billion ≈ $17.28 Million |
-- |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more